To evaluate a possible physiological role of endogenous substance P (SP) in the control of growth hormone (GH; somatotropin) secretion, a specific antiserum against SP (anti-SP) was injected intraventricularly (3 I1 into the third cerebral ventricle) in unanesthetized unrestrained normal male rats. Control rats received an equivalent volume of normal rabbit serum (NRS). Intraventricular iniection of the NRS lowered plasma GH concentrations significantly. The lowering was detected on first measurement at 10 min after injection and was maximal at 30 min. This was followed by a return toward the initial levels. Third ventricular injection of antiserum significantly increased plasma GH in comparison with control animals injected with NRS. The effect was observed within 10-20 min, and levels remained elevated for the 120-min duration of the experiment. To confirm the possible inhibitory role of endogenous SP on GH release, 3 pl of 0.9% NaCl (saline) alone or saline containing a specific antagonist of SP, was injected into the third ventricle of normal male rats. The antagonist also increased plasma GH sigicantly (P < 0.005) within 5 min compared with values in the saline-injected control group. Levels remained elevated for 30 min but had returned toward control values 60 min after injection. In contrast, synthetic SP significantly decreased plasma GH when injected intravenously or intraventricularly compared with plasma GH in the control saline-injected group.
ABSTRACT
To evaluate a possible physiological role of endogenous substance P (SP) in the control of growth hormone (GH; somatotropin) secretion, a specific antiserum against SP (anti-SP) was injected intraventricularly (3 I1 into the third cerebral ventricle) in unanesthetized unrestrained normal male rats. Control rats received an equivalent volume of normal rabbit serum (NRS). Intraventricular iniection of the NRS lowered plasma GH concentrations significantly. The lowering was detected on first measurement at 10 min after injection and was maximal at 30 min. This was followed by a return toward the initial levels. Third ventricular injection of antiserum significantly increased plasma GH in comparison with control animals injected with NRS. The effect was observed within 10-20 min, and levels remained elevated for the 120-min duration of the experiment. To confirm the possible inhibitory role of endogenous SP on GH release, 3 pl of 0.9% NaCl (saline) alone or saline containing a specific antagonist of SP, [D-Pro2,D-Trp7"jSP, was injected into the third ventricle of normal male rats. The antagonist also increased plasma GH sigicantly (P < 0.005) within 5 min compared with values in the saline-injected control group. Levels remained elevated for 30 min but had returned toward control values 60 min after injection. In contrast, synthetic SP significantly decreased plasma GH when injected intravenously or intraventricularly compared with plasma GH in the control saline-injected group.
To investigate a possible direct action of SP on GH release from the anterior pituitary gland, we incubated synthetic SP with dispersed anterior pituitary cells for 1 hr. The release of GH from incubated anterior pituitary cells was not affected at any dose of SP (10-' to 10-6 M) tested. These data strongly indicate that endogenous SP has a physiological inhibitory role in the control of GH secretion at the level of the hypothalamus in the male rat. Substance P (SP) was originally detected in equine brain and intestine by Von Euler and Gaddum in 1931 (1) . This undecapeptide was isolated from the hypothalamus and characterized by Leeman in 1970-1971 (2, 3) . Immunocytochemical studies have demonstrated an SP-containing neuronal system in the hypothalamus (4) (5) (6) (7) (8) (9) (10) , and the peptide has been localized to cells of the anterior pituitary gland as well (11, 12) . In addition, SP receptors have been localized to various regions of the hypothalamus and pituitary (5, 6 (R-11) has been fully characterized (11) and is directed at the carboxyl terminus. Peptides structurally related to Harms and Ojeda (14) while the animal was anesthetized with ether. On the morning of the experiment, the animal was left undisturbed for at least 60 min. Three microliters of undiluted antiserum or an equal volume of normal rabbit serum (NRS) was administered immediately after withdrawal of the first blood sample (0.8 ml). Blood samples (0.8 ml) were withdrawn at various time intervals thereafter. In this and subsequent experiments, each blood sample was replaced with an equal volume (0.8 ml) of saline (0.9% NaCl).
Experiment II. In rats with indwelling 3V cannulae 3 plI of the undiluted antiserum or an equal volume of NRS was injected intraventricularly 24 hr before the initial blood sampling and just prior to implantation of a catheter in the external jugular vein. On the day of the experiment, one blood sample was withdrawn and the animal was injected intraventricularly with 3 tL4 of the undiluted antiserum or NRS. Blood samples were withdrawn at various time intervals thereafter as described above.
Experiment III. In rats with implanted ventricular and jugular cannulae, [D-Pro2,D-Trp7'9]SP (50 ng in 3 1ul of saline) or an equal volume of saline was injected into the 3V immediately after the initial blood sampling. Blood samples were taken thereafter as described above.
Experiment IV. To evaluate the effect of SP itself, synthetic SP dissolved in 3 dul of 0.9% NaCl, or an equal volume of saline alone, was injected into the 3V in rats implanted with ventricular and jugular cannulae immediately after the first blood sample (0.8 ml) was withdrawn. Blood samples (0.8 ml) were withdrawnjust prior to intraventricular injections and at various time intervals thereafter. Experiment V. In rats bearing only jugular catheters, an initial blood sample was withdrawn and various doses of SP were injected intravenously (i.v.). Blood samples were withdrawn at various intervals thereafter.
In Vito Experiments. Anterior pituitaries were removed from adult male rats after decapitation and dispersed in the presence of 0.1% trypsin as previously described (15) . Cells were incubated overnight at 370C in medium 199 containing 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes) (GIBCO), 10%6 horse serum, and penicillinstreptomycin (1 ml/100 ml; GIBCO). On the day of experimentation, overnight culture medium was removed. The cells were incubated for 30 min in the above medium without horse serum but containing 0.1% bovine serum albumin (GIBCO). Then they were resuspended in either 1 ml of this medium alone or 1 ml of the same medium containing appropriate test substances. The incubation was terminated after 60 min.
After centrifugation media were stored frozen at -200C for subsequent analyses by radioimmunoassay.
Hormone Assays. GH was measured by specific radioimmunoassay using a kit supplied by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). NIDDK-rat-GH-RP-1 was used as the reference preparation for each assay.
Statistical Analysis. The significance of the changes between pre-and postinjection levels of GH was calculated by using one-way analysis of variance and the StudentNewman-Keul multiple comparison test for unequal replication. Data plasma GH as compared to control animals injected with NRS ( Fig. 1 Upper) . The effect was observed within 20 min after administration and plasma GH remained elevated for 180 min. Fig. 1 Lower depicts the area under the curve of plasma GH in both groups for the first hour and the initial 2 hr after injection. The area under the plasma GH curve of the anti-SP-injected group was increased more than 2-fold as compared to that of the control group at both time points.
To confirm the stimulatory effect of anti-SP on GH secretion, anti-SP or NRS was injected into the 3V 24 hr prior to the experiment. The injections were repeated just after removal of the first blood sample. This double-injection protocol was followed since it had been found effective in previous passive immunization experiments (16) . Although plasma GH was not significantly altered 24 hr after the injection in comparison with the values in the NRS-injected control groups, there was a greater effect of the second intraventricular injection of antiserum than that seen after a single injection. Plasma GH was already significantly higher within 10 min after the second injection compared to the decreased levels of control animals which received two injections of NRS (Fig. 2 Upper). The difference between groups was maintained for the 90-min duration of the experiment. When the area under the curve of plasma GH was determined on both groups, the area was significantly greater (P < 0.01) for the anti-SP-injected group than for the control group (Fig. 2 Lower) .
Effect of Intraventricular Injection of the SP Antagonist.
[D-Pro2,D-Trp7'9]SP caused a significant increase of plasma Physiology: Arisawa et al. GH within 5 min of its injection into the 3V, and the levels remained elevated for 30 min after injection compared with levels in the saline-injected control group (P < 0.01) (Fig. 3 Upper). By 60 min after injection, values had returned toward control levels. The area under the plasma GH curves of both groups revealed a highly significant increase (P < 0.005) in area in the antagonist-injected rats above that of diluentinjected animals (Fig. 3 Lower) .
Effect (Fig. 4) 5 . Effect of i.v. injected (arrow) SP or physiological saline on GH release in unanesthetized normal male rats. *, P < 0.005; **, P < 0.001 vs. control value at the same time. t, P < 0.025; tt, P < 0.01; ttt, P < 0.001 vs. zero-time sample.
significant effect on the release of GH into the culture medium, but the cells were responsive to GHRH (Table 1) .
DISCUSSION
The present results indicate that both a specific antiserum against SP and a specific antagonist of the peptide can cause an increase of plasma GH when injected into the 3V of male rats. In contrast, exogenous SP suppressed the release of GH when administered either intravenously or intraventricularly. The minimal effective dose after 3V injection was less than that after i.v. injection, which indicates a central inhibitory action of SP. These data strongly suggest that endogenous SP has a physiological inhibitory role in the control of GH secretion at the hypothalamic level in normal male rats. In most instances the control injections of either saline or NRS suppressed plasma GH in these animals, which was probably related to a stress-induced inhibition of GH release (17) . Therefore, part of the action of the antiserum or the antagonist may be related to the blockade of stress-induced somatostatin release; however, since the antagonist elevated plasma GH to levels clearly above normal, it would appear that GHRH release was stimulated as well.
To date, both inhibitory and stimulatory effects of SP upon GH release have been reported, and the physiological role of this peptide in the control of GH secretion is still controversial (4-6). It was reported that systemic administration of SP stimulated GH release in urethane-anesthetized male rats (18, 19) . However, in the present study, we were unable to stimulate GH secretion with 1, 10, or 50 jig of SP in conscious, freely moving normal male rats. To confirm the effect ofi.v. SP on GH release, we injected the same amounts of SP (1, 10 , and 50 ug per animal) as used here into ovariectomized unanesthetized rats and unanesthetized estrogen-progesterone-primed ovariectomized rats. No stimu- (20) . 3V injection of SP into ovariectomized, conscious female rats was reported to cause an increase in plasma GH (21), whereas Chihara et al. (22) , in agreement with the present results, reported the inhibitory effect of this peptide when injected into the lateral ventricle of urethane-anesthetized male rats. They postulated that SP may exert an inhibitory effect on GH secretion via hypothalamic release of somatostatin, since the effect of SP was blocked in animals previously injected with antiserum to somatostatin. Other investigators (23) reported increased in vitro release of somatostatin from hypothalamic fragments incubated in the presence of SP, which supports the concept that the central inhibitory effect of SP on GH may be mediated by somatostatin. On the other hand, Takahara et al. (24) found that intraventricularly injected SP itself had no effect on serum GH, but it inhibited the y-aminobutyric acid-induced increases in serum GH. In the rhesus monkey, SP was also reported to induce a significant decrease in GH secretion (24) .
It is difficult to assign a physiological role for SP in the control of GH secretion from injections of the peptide, since microgram quantities of SP might have some pharmacological effect on the central nervous system when injected intraventricularly, and systemic administration of SP could induce changes in blood pressure or other effects and provoke a stress response. Therefore, neutralization of endogenous SP by the use of an antiserum or an antagonist is an effective method to investigate the physiological role of SP.
In this study, we demonstrated that synthetic SP inhibits GH release, whereas anti-SP and an antagonist to the peptide had the opposite effect, increasing plasma GH after administration into the 3V. In view of these findings and our in vitro results which showed no direct effect of SP on the release of GH from anterior pituitary cells, we conclude that, in unanesthetized freely moving male rats, SP exerts an inhibitory role in the control of basal release of GH at the level of the hypothalamus.
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